X

Trial Profile

A Phase III, Open Label, Multicenter, Single Arm Study to Assess the Safety, Tolerability and Immunogenicity of VLA2001 in Volunteers Aged ≥ 56 Years

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VLA 2001 (Primary) ; VLA 2101 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics; Registrational
Sponsors Valneva

Most Recent Events

31 Aug 2023 Status changed from active, no longer recruiting to completed.
14 Jan 2022 Planned End Date changed from 1 Mar 2023 to 1 Sep 2022.
20 Oct 2021 Planned number of patients changed from 750 to 900.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com